Insulin Market Growth Driven by Rising Diabetes Prevalence and Advancements in Delivery Technologies

The global insulin market was valued at USD 570.8 million in 2022 and is projected to register a steady revenue CAGR of 3.3% during the forecast period. A major factor contributing to this growth is the rising prevalence of obesity, sedentary lifestyles, and unhealthy eating habits, which are all closely linked to increasing diabetes cases. Insulin plays a critical role in regulating blood glucose levels by facilitating the absorption of glucose into the bloodstream. In clinical settings, insulin is commonly administered intravenously, subcutaneously, or intramuscularly to manage hyperglycemia.

According to the International Diabetes Federation (IDF), approximately 537 million adults aged 20 to 79 were living with diabetes in 2021, with nearly half-around 240 million-remaining undiagnosed. Diabetes was also responsible for approximately 6.7 million deaths globally in that year. These figures underscore the growing global health burden of diabetes and the essential role of insulin in its treatment.

Get a sample of the report @ https://www.emergenresearch.com/request-sample/2584

The insulin market is primarily driven by the increasing number of diabetes cases, continuous innovation in insulin products, and growing government efforts to raise awareness about diabetes and insulin use. Since diabetes disrupts the normal insulin-mediated uptake of glucose into cells, daily insulin administration becomes necessary for many patients. As the number of people living with diabetes continues to climb, so too does the demand for insulin. The IDF estimates this number will increase to 643 million by 2030 and 783 million by 2045, reflecting the urgent need for insulin solutions.

Government initiatives to enhance public awareness and access to diabetes care are also positively influencing the market. For example, in November 2023, the World Health Organization launched a global campaign focused on access to diabetes care, aiming to promote early detection and effective treatment. Such campaigns are expected to significantly boost public knowledge and demand for insulin therapies.

In addition, advances in insulin delivery systems are contributing to market expansion. Notably, in March 2024, researchers backed by the European Union initiated the BuBble Gun project, which explores a needle-free method of insulin delivery by depositing liquid into skin and soft tissue using compression. This innovation, expected to conclude by the end of 2024, holds promise especially for the elderly and those with needle-related discomfort, thereby supporting the growth of the non-injectable insulin segment.

In summary, the insulin market is being driven by the rising global burden of diabetes, the launch of advanced insulin products, continuous innovation in delivery systems, and proactive public health campaigns. These factors are expected to collectively propel the growth of the insulin market over the forecast period.

Market Dynamics - Drivers

The insulin market is experiencing significant growth due to the surging global prevalence of diabetes and the continuous evolution of insulin delivery technologies. As unhealthy diets, obesity, and physical inactivity become more widespread, diabetes has emerged as a critical global health challenge. This rising disease burden is evident not only in developed countries but also in emerging economies, thereby expanding the global need for insulin therapies. Manufacturers are scaling up production and research efforts to cater to this growing demand.

Additionally, technological advancements in insulin delivery methods are enhancing patient experience and boosting market demand. Innovations such as smart insulin pens, wearable insulin pumps, and integrated glucose monitoring systems have transformed the way patients manage their condition. These devices improve the accuracy of insulin dosing, increase convenience, and encourage adherence to treatment, which are crucial for effective diabetes management. The integration of healthcare and technology is making insulin therapy more accessible and user-friendly, driving further growth in the global insulin market.

Some major players included in the global insulin market report are:

Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Biocon Limited
Medtronic Plc.
Pfizer Inc.
Merck & Co., Inc.
Becton, Dickinson and Company (BD)
Braun SE
Biomm

14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.